HC Wainwright set a $4.00 target price on Aptose Biosciences, Inc. (NASDAQ:APTO) (TSE:APS) in a research note published on Wednesday morning. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other equities analysts have also recently issued reports on the company. ValuEngine upgraded Aptose Biosciences from a strong sell rating to a sell rating in a report on Tuesday, October 31st. Zacks Investment Research upgraded Aptose Biosciences from a hold rating to a buy rating and set a $1.50 price objective for the company in a report on Monday, August 14th. Finally, Roth Capital reiterated a buy rating and issued a $5.00 price objective on shares of Aptose Biosciences in a report on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $4.50.

Aptose Biosciences (APTO) traded up $0.15 on Wednesday, hitting $1.92. The stock had a trading volume of 270,837 shares, compared to its average volume of 396,731. Aptose Biosciences has a 1 year low of $0.78 and a 1 year high of $2.20.

WARNING: This report was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.dailypolitical.com/2017/11/18/hc-wainwright-reiterates-4-00-price-target-for-aptose-biosciences-inc-apto.html.

About Aptose Biosciences

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.